Capecitabine
- Generic Name
- Capecitabine
- Brand Names
- Ecansya, Xeloda, Capecitabine Medac, Ecansya (previously Capecitabine Krka), Capecitabine Accord, Capecitabine Teva
- Drug Type
- Small Molecule
- Chemical Formula
- C15H22FN3O6
- CAS Number
- 154361-50-9
- Unique Ingredient Identifier
- 6804DJ8Z9U
- Background
Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
- Indication
Capecitabine is indicated as treatment for a variety of cancer types. For colorectal cancer, capecitabine is indicated as a single agent or a component of a combination chemotherapy regiment for the adjuvant treatment of stage III colon cancer and treatment unresectable or metastatic colorectal cancer. It can also be used as a part of a combination chemotherapy perioperative treatment of adult locally advanced rectal cancer. For breast cancer, capecitabine is indicated for advanced or metastatic breast cancer as a single agent if an anthracycline- or taxane-containing chemotherapy is not indicated or as a regimen with docetaxel after disease progression on prior anthracycline-containing chemotherapy. For gastric, esophageal, or gastroesophageal junction (GEJ) cancer, capecitabine is indicated as a component of a combination chemotherapy treatment for the treatment of adult unresectable or metastatic gastric, esophageal, or GEJ cancer or adult HER2-overexpressing metastatic gastric or GEJ adenocarcinoma who have not received prior treatment for metastatic disease. Finally, for pancreatic cancer, capecitabine is indicated as adjuvant treatment for adult pancreatic adenocarcinoma as a component of a combination chemotherapy regimen.
- Associated Conditions
- Advanced or Metastatic Breast Cancer, Carcinoma of Gallbladder, Cholangiocarcinoma, Hepatocellular Carcinoma, Locally Advanced Rectal Cancer (LARC), Metastatic Adenocarcinoma of the Gastroesophageal Junction, Metastatic Gastric Cancers, Metastatic Neuroendocrine Tumors, Pancreatic Adenocarcinoma, Pancreatic Cancer, Advanced or Metastatic, Platinum-resistant Epithelial Ovarian Cancer, Refractory Fallopian Tube Carcinoma, Stage III Colon Cancer, Unresectable or Metastatic Colorectal Cancer, Metastatic pancreatic endocrine carcinoma, Refractory peritoneal cancer, Refractory, metastatic Colorectal carcinoma, Unresectable, metastatic Esophageal Cancer, Unresectable, metastatic Gastric Cancer, Unresectable, metastatic Gastroesophageal Junction Cancer
- Associated Therapies
- Chemotherapy
Tolerance and Pharmacokinetics With Capecitabine 5 Out of 7 Days Regimen
- Conditions
- First Posted Date
- 2006-05-11
- Last Posted Date
- 2006-05-18
- Target Recruit Count
- 46
- Registration Number
- NCT00324610
- Locations
- 🇫🇷
Ho¨Pital Europeen Georges Pompidou, Paris, France
Bevacizumab, Radiation Therapy, and Combination Chemotherapy in Treating Patients Who Are Undergoing Surgery for Locally Advanced Nonmetastatic Rectal Cancer
- First Posted Date
- 2006-05-04
- Last Posted Date
- 2019-03-27
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 57
- Registration Number
- NCT00321685
- Locations
- 🇺🇸
Einstein Medical Center Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸Sparta Cancer Treatment Center, Sparta, New Jersey, United States
🇺🇸Nebraska Cancer Research Center, Lincoln, Nebraska, United States
Capecitabine, Docetaxel and Gemcitabine in Patients With Advanced Pancreas Cancer
- Conditions
- Interventions
- First Posted Date
- 2006-05-03
- Last Posted Date
- 2016-06-27
- Lead Sponsor
- Tony Bekaii-Saab
- Target Recruit Count
- 21
- Registration Number
- NCT00320749
- Locations
- 🇺🇸
The University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
🇺🇸Ohio State University, Columbus, Ohio, United States
Combination of Cetuximab, Capecitabine, and Oxaliplatin With or Without Bevacizumab
- Conditions
- Interventions
- First Posted Date
- 2006-05-03
- Last Posted Date
- 2022-01-12
- Lead Sponsor
- Fox Chase Cancer Center
- Target Recruit Count
- 23
- Registration Number
- NCT00321100
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Study of Bevacizumab Combined With Capecitabine and Either Oxaliplatin or Irinotecan as First Course of Treatment for Patients With Colorectal Cancer That Has Spread Beyond the Colon
- Conditions
- Interventions
- First Posted Date
- 2006-04-13
- Last Posted Date
- 2021-10-06
- Lead Sponsor
- NSABP Foundation Inc
- Target Recruit Count
- 7
- Registration Number
- NCT00314353
- Locations
- 🇺🇸
NSABP Operations Center, Pittsburgh, Pennsylvania, United States
Randomized Neoadjuvant Study of Epirubicin and Docetaxel With/Without Capecitabine in Early Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2006-04-03
- Last Posted Date
- 2011-12-30
- Lead Sponsor
- Austrian Breast & Colorectal Cancer Study Group
- Target Recruit Count
- 536
- Registration Number
- NCT00309556
- Locations
- 🇦🇹
Hospital BHB St. Veit/Glan, Surgery, St. Veit a. d. Glan, Carinthia, Austria
🇦🇹State Hospital Klagenfurt, Klagenfurt, Carinthia, Austria
🇦🇹Hospital Guessing, Guessing, Burgenland, Austria
Celecoxib in Preventing Hand/Foot Syndrome Caused By Capecitabine With Metastatic Breast or Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2006-03-22
- Last Posted Date
- 2015-12-24
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 11
- Registration Number
- NCT00305643
- Locations
- 🇺🇸
Cancer Research for the Ozarks, Springfield, Missouri, United States
🇺🇸CCOP - Columbus, Columbus, Ohio, United States
🇺🇸CCOP - Kalamazoo, Kalamazoo, Michigan, United States
Bevacizumab or Cetuximab And Gemcitabine Hydrochloride, Capecitabine, and Radiation Therapy in Treating Patients With Pacreatic Cancer That Has Been Completely Removed By Surgery
- Conditions
- Interventions
- First Posted Date
- 2006-03-22
- Last Posted Date
- 2014-05-21
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 137
- Registration Number
- NCT00305877
- Locations
- 🇺🇸
Eastern Cooperative Oncology Group, Boston, Massachusetts, United States
Capecitabine as Second-Line Therapy in Treating Patients With Stage IV Pancreatic Cancer Who Have the Thymidylate Synthase Gene
- Conditions
- First Posted Date
- 2006-03-17
- Last Posted Date
- 2010-03-19
- Target Recruit Count
- 65
- Registration Number
- NCT00303927
- Locations
- 🇪🇸
Hospital Universitario 12 de Octubre, Madrid, Spain
🇺🇸Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
Irinotecan With or Without Capecitabine as Second-Line Therapy in Treating Older Patients With Progressive, Metastatic Colorectal Cancer That Cannot Be Removed By Surgery
- Conditions
- First Posted Date
- 2006-03-17
- Last Posted Date
- 2008-07-24
- Lead Sponsor
- Federation Francophone de Cancerologie Digestive
- Target Recruit Count
- 78
- Registration Number
- NCT00303745
- Locations
- 🇫🇷
Centre Hospitalier, Chalon Sur Saone, France
🇫🇷Centre Hospitalier Universitaire Ambroise Pare - Boulogne, Boulogne, France
🇫🇷Clinique Pasteur, Guilherand Granges, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.